Cetera Investment Advisers
RPRX icon

Cetera Investment Advisers’s Royalty Pharma RPRX Stock Holding History

Cetera Investment Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.74M Buy
84,520
+7,604
+10% +$396K ﹤0.01% 1663
2026
Q1 		$3.69M Buy
76,916
+5,180
+7% +$227K ﹤0.01% 1732
2025
Q4 		$2.77M Sell
71,736
-964
-1% -$36.8K ﹤0.01% 1929
2025
Q3 		$2.56M Buy
72,700
+63,227
+667% +$2.29M ﹤0.01% 1962
2025
Q2 		$341K Sell
9,473
-353
-4% -$11.7K ﹤0.01% 3286
2025
Q1 		$306K Buy
+9,826
New +$311K ﹤0.01% 3250
2024
Q2 		– Sell
-7,318
Closed -$222K – 3831
2024
Q1 		$222K Buy
+7,318
New +$216K ﹤0.01% 3286

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cetera Investment Advisers's RPRX Position: Q2 2026 in Review

Cetera Investment Advisers increased its Royalty Pharma (RPRX) stake by 9.9% in Q2 2026, buying an estimated $396K and bringing the position to 84,520 shares worth $4.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1663.

Cetera Investment Advisers first reported a position in RPRX in Q1 2024 and has held it in 7 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Cetera Investment Advisers held 84,520 shares of Royalty Pharma worth $4.74M as of Q2 2026.
  • Cetera Investment Advisers bought 7,604 Royalty Pharma shares in Q2 2026, an estimated $396K.
  • Royalty Pharma made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #1663 holding.
  • Cetera Investment Advisers first reported a position in Royalty Pharma in Q1 2024 and has held it in 7 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.